Liver Diseases  >>  ribavirin  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ribavirin / Generic mfg.
NCT00700401: POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).

Completed
N/A
262
RoW
peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
Hoffmann-La Roche
Hepatitis C, Chronic
11/10
11/10
RE-CHUT, NCT00725842: Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)

Terminated
N/A
97
Europe
Peg-IFN alfa-2b, SCH 054031, Ribavirin, SCH 018908
Merck Sharp & Dohme LLC
Hepatitis C, Hepatitis C, Chronic
06/11
06/11
NCT01200225: An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

Completed
N/A
1155
Europe
Hoffmann-La Roche
Hepatitis C, Chronic
06/13
06/13
NCT01392742: An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin

Completed
N/A
443
Europe
Hoffmann-La Roche
Hepatitis C, Chronic
07/14
07/14
PEGHOPE, NCT01416610: An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy

Completed
N/A
88
Europe
Hoffmann-La Roche
Hepatitis C, Chronic
10/14
10/14
NCT02118597: An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients

Terminated
N/A
19
Europe
Boceprevir, Victrelis, Simeprevir, Olysio, Pegylated Interferon (Peginterferon) Alfa-2a, Pegasys, Ribavirin, Copegus
Hoffmann-La Roche
Hepatitis C, Chronic
05/15
05/15
NCT01659567: A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C

Completed
N/A
516
RoW
Pegylated Interferon Alfa-2a, Pegasys, Ribavirin, Copegus
Hoffmann-La Roche
Hepatitis C, Chronic
10/15
10/15
NCT02097966: EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C

Checkmark VHC 2015
Sep 2015 - Sep 2015: VHC 2015
Checkmark ILC 2015
Apr 2015 - Apr 2015: ILC 2015
Checkmark VHC 2014
More
No Longer Available
N/A
Europe
Daclatasvir, BMS-790052, Sofosbuvir, Ribavirin
Bristol-Myers Squibb
Chronic Hepatitis C
 
 
RHACE 1, NCT02098616: Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus

Completed
N/A
25
US
DCV/ASV/BMS-791325, Fixed Dose Combination (FDC) of Daclatasvir/Asunaprevir/BMS-791325, DCV/ASV/BMS-791325 + RBV
Timothy Morgan, MD, VA Long Beach Healthcare System, National Cancer Institute (NCI), Bristol-Myers Squibb
Hepatitis C
02/16
02/16

Download Options